Evaluation of Gender Inequity in Thyroid Cancer Diagnosis: Differences by Sex in US Thyroid Cancer Incidence Compared With a Meta-analysis of Subclinical Thyroid Cancer Rates at Autopsy
Thyroid cancer is more common in women than in men, but the associated causes of these differences are not fully understood. To compare sex-specific thyroid cancer rates in the US to the prevalence of subclinical thyroid cancer at autopsy. Data on thyroid cancer incidence and mortality by sex among...
Gespeichert in:
| Veröffentlicht in: | JAMA internal medicine Jg. 181; H. 10; S. 1351 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.10.2021
|
| Schlagworte: | |
| ISSN: | 2168-6114, 2168-6114 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Thyroid cancer is more common in women than in men, but the associated causes of these differences are not fully understood.
To compare sex-specific thyroid cancer rates in the US to the prevalence of subclinical thyroid cancer at autopsy.
Data on thyroid cancer incidence and mortality by sex among US adults (≥18 years) were extracted from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program (SEER) data for 1975 to 2017. Embase, PubMed, and Web of Science databases were searched for studies on the prevalence of subclinical thyroid cancer at autopsy of men and women, from inception to May 31, 2021.
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was used to perform a systematic search for articles reporting the prevalence of subclinical thyroid cancer in autopsy results of both women and men. Of 101 studies identified, 8 studies containing 12 data sets met inclusion criteria; ie, they examined the whole thyroid gland, stated the number of thyroids examined, and reported results by sex. Excluded studies reported thyroid cancer in Japan after the atomic bombs or Chernobyl after the nuclear disaster; did not examine the whole thyroid gland or had incomplete information on thyroid examination methods; or did not report rates by sex.
Thyroid cancer incidence and mortality data by sex, histologic type, and tumor size were extracted from SEER. The inverse variance heterogeneity model was used to meta-analyze the prevalence and the odds ratio of subclinical thyroid cancer by sex from 8 studies (12 data sets) on thyroid cancer prevalence in autopsy results.
Incidence and mortality of thyroid cancer, by histologic type and tumor size; prevalence of thyroid cancer in autopsy results.
In 2017, 90% of thyroid cancers diagnosed were papillary thyroid cancer (PTC) and in 2013 to 2017, the women to men incidence ratio for small (≤2 cm) PTC was 4.39:1. The incidence ratio approached 1:1 as cancer type lethality increased. The ratio of thyroid cancer mortality by gender was 1.02:1 and remained stable from 1992 to 2017. Results of the meta-analysis showed that the pooled autopsy prevalence of subclinical PTC was 14% in women (95% CI, 8%-20%) and 11% in men (95% CI, 5%-18%). The pooled odds ratio of subclinical PTC in women compared with men was 1.07 (95% CI, 0.80-1.42).
This cohort study and meta-analysis found that the belief that women get thyroid cancer more often than men is an oversimplification. The gender disparity is mostly confined to the detection of small subclinical PTCs, which are equally common in both sexes at autopsy but identified during life much more often in women than men. As the lethality of the cancer type increases, the ratio of detection by gender approaches 1:1. This phenomenon may be associated with gender differences in health care utilization and patterns of clinical thinking and can harm both women, who are subject to overdetection, and men, who may be at risk of underdetection. |
|---|---|
| AbstractList | Thyroid cancer is more common in women than in men, but the associated causes of these differences are not fully understood.
To compare sex-specific thyroid cancer rates in the US to the prevalence of subclinical thyroid cancer at autopsy.
Data on thyroid cancer incidence and mortality by sex among US adults (≥18 years) were extracted from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program (SEER) data for 1975 to 2017. Embase, PubMed, and Web of Science databases were searched for studies on the prevalence of subclinical thyroid cancer at autopsy of men and women, from inception to May 31, 2021.
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was used to perform a systematic search for articles reporting the prevalence of subclinical thyroid cancer in autopsy results of both women and men. Of 101 studies identified, 8 studies containing 12 data sets met inclusion criteria; ie, they examined the whole thyroid gland, stated the number of thyroids examined, and reported results by sex. Excluded studies reported thyroid cancer in Japan after the atomic bombs or Chernobyl after the nuclear disaster; did not examine the whole thyroid gland or had incomplete information on thyroid examination methods; or did not report rates by sex.
Thyroid cancer incidence and mortality data by sex, histologic type, and tumor size were extracted from SEER. The inverse variance heterogeneity model was used to meta-analyze the prevalence and the odds ratio of subclinical thyroid cancer by sex from 8 studies (12 data sets) on thyroid cancer prevalence in autopsy results.
Incidence and mortality of thyroid cancer, by histologic type and tumor size; prevalence of thyroid cancer in autopsy results.
In 2017, 90% of thyroid cancers diagnosed were papillary thyroid cancer (PTC) and in 2013 to 2017, the women to men incidence ratio for small (≤2 cm) PTC was 4.39:1. The incidence ratio approached 1:1 as cancer type lethality increased. The ratio of thyroid cancer mortality by gender was 1.02:1 and remained stable from 1992 to 2017. Results of the meta-analysis showed that the pooled autopsy prevalence of subclinical PTC was 14% in women (95% CI, 8%-20%) and 11% in men (95% CI, 5%-18%). The pooled odds ratio of subclinical PTC in women compared with men was 1.07 (95% CI, 0.80-1.42).
This cohort study and meta-analysis found that the belief that women get thyroid cancer more often than men is an oversimplification. The gender disparity is mostly confined to the detection of small subclinical PTCs, which are equally common in both sexes at autopsy but identified during life much more often in women than men. As the lethality of the cancer type increases, the ratio of detection by gender approaches 1:1. This phenomenon may be associated with gender differences in health care utilization and patterns of clinical thinking and can harm both women, who are subject to overdetection, and men, who may be at risk of underdetection. Thyroid cancer is more common in women than in men, but the associated causes of these differences are not fully understood.ImportanceThyroid cancer is more common in women than in men, but the associated causes of these differences are not fully understood.To compare sex-specific thyroid cancer rates in the US to the prevalence of subclinical thyroid cancer at autopsy.ObjectiveTo compare sex-specific thyroid cancer rates in the US to the prevalence of subclinical thyroid cancer at autopsy.Data on thyroid cancer incidence and mortality by sex among US adults (≥18 years) were extracted from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program (SEER) data for 1975 to 2017. Embase, PubMed, and Web of Science databases were searched for studies on the prevalence of subclinical thyroid cancer at autopsy of men and women, from inception to May 31, 2021.Data SourcesData on thyroid cancer incidence and mortality by sex among US adults (≥18 years) were extracted from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program (SEER) data for 1975 to 2017. Embase, PubMed, and Web of Science databases were searched for studies on the prevalence of subclinical thyroid cancer at autopsy of men and women, from inception to May 31, 2021.The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was used to perform a systematic search for articles reporting the prevalence of subclinical thyroid cancer in autopsy results of both women and men. Of 101 studies identified, 8 studies containing 12 data sets met inclusion criteria; ie, they examined the whole thyroid gland, stated the number of thyroids examined, and reported results by sex. Excluded studies reported thyroid cancer in Japan after the atomic bombs or Chernobyl after the nuclear disaster; did not examine the whole thyroid gland or had incomplete information on thyroid examination methods; or did not report rates by sex.Study SelectionThe Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was used to perform a systematic search for articles reporting the prevalence of subclinical thyroid cancer in autopsy results of both women and men. Of 101 studies identified, 8 studies containing 12 data sets met inclusion criteria; ie, they examined the whole thyroid gland, stated the number of thyroids examined, and reported results by sex. Excluded studies reported thyroid cancer in Japan after the atomic bombs or Chernobyl after the nuclear disaster; did not examine the whole thyroid gland or had incomplete information on thyroid examination methods; or did not report rates by sex.Thyroid cancer incidence and mortality data by sex, histologic type, and tumor size were extracted from SEER. The inverse variance heterogeneity model was used to meta-analyze the prevalence and the odds ratio of subclinical thyroid cancer by sex from 8 studies (12 data sets) on thyroid cancer prevalence in autopsy results.Data Extraction and SynthesisThyroid cancer incidence and mortality data by sex, histologic type, and tumor size were extracted from SEER. The inverse variance heterogeneity model was used to meta-analyze the prevalence and the odds ratio of subclinical thyroid cancer by sex from 8 studies (12 data sets) on thyroid cancer prevalence in autopsy results.Incidence and mortality of thyroid cancer, by histologic type and tumor size; prevalence of thyroid cancer in autopsy results.Main Outcomes and MeasuresIncidence and mortality of thyroid cancer, by histologic type and tumor size; prevalence of thyroid cancer in autopsy results.In 2017, 90% of thyroid cancers diagnosed were papillary thyroid cancer (PTC) and in 2013 to 2017, the women to men incidence ratio for small (≤2 cm) PTC was 4.39:1. The incidence ratio approached 1:1 as cancer type lethality increased. The ratio of thyroid cancer mortality by gender was 1.02:1 and remained stable from 1992 to 2017. Results of the meta-analysis showed that the pooled autopsy prevalence of subclinical PTC was 14% in women (95% CI, 8%-20%) and 11% in men (95% CI, 5%-18%). The pooled odds ratio of subclinical PTC in women compared with men was 1.07 (95% CI, 0.80-1.42).ResultsIn 2017, 90% of thyroid cancers diagnosed were papillary thyroid cancer (PTC) and in 2013 to 2017, the women to men incidence ratio for small (≤2 cm) PTC was 4.39:1. The incidence ratio approached 1:1 as cancer type lethality increased. The ratio of thyroid cancer mortality by gender was 1.02:1 and remained stable from 1992 to 2017. Results of the meta-analysis showed that the pooled autopsy prevalence of subclinical PTC was 14% in women (95% CI, 8%-20%) and 11% in men (95% CI, 5%-18%). The pooled odds ratio of subclinical PTC in women compared with men was 1.07 (95% CI, 0.80-1.42).This cohort study and meta-analysis found that the belief that women get thyroid cancer more often than men is an oversimplification. The gender disparity is mostly confined to the detection of small subclinical PTCs, which are equally common in both sexes at autopsy but identified during life much more often in women than men. As the lethality of the cancer type increases, the ratio of detection by gender approaches 1:1. This phenomenon may be associated with gender differences in health care utilization and patterns of clinical thinking and can harm both women, who are subject to overdetection, and men, who may be at risk of underdetection.Conclusions and RelevanceThis cohort study and meta-analysis found that the belief that women get thyroid cancer more often than men is an oversimplification. The gender disparity is mostly confined to the detection of small subclinical PTCs, which are equally common in both sexes at autopsy but identified during life much more often in women than men. As the lethality of the cancer type increases, the ratio of detection by gender approaches 1:1. This phenomenon may be associated with gender differences in health care utilization and patterns of clinical thinking and can harm both women, who are subject to overdetection, and men, who may be at risk of underdetection. |
| Author | Doi, Suhail A Bell, Katy J L Furuya-Kanamori, Luis Francis, David O LeClair, Karissa Davies, Louise |
| Author_xml | – sequence: 1 givenname: Karissa surname: LeClair fullname: LeClair, Karissa organization: Geisel School of Medicine at Dartmouth, Hanover, New Hampshire – sequence: 2 givenname: Katy J L surname: Bell fullname: Bell, Katy J L organization: Faculty of Medicine and Health, Sydney School of Public Health, The University of Sydney, New South Wales, Australia – sequence: 3 givenname: Luis surname: Furuya-Kanamori fullname: Furuya-Kanamori, Luis organization: The University of Queensland Centre for Clinical Research, The University of Queensland, Herston, Australia – sequence: 4 givenname: Suhail A surname: Doi fullname: Doi, Suhail A organization: Department of Population Medicine, College of Medicine, Qatar University Health, Qatar University, Doha, Qatar – sequence: 5 givenname: David O surname: Francis fullname: Francis, David O organization: Wisconsin Surgical Outcomes Research and Division of Otolaryngology, Department of Surgery, University of Wisconsin, Madison – sequence: 6 givenname: Louise surname: Davies fullname: Davies, Louise organization: The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, New Hampshire |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34459841$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdUcFKAzEQDVKxWv0FzdHL1iTNZrfepFYtVARb8Vgm2axN2U3qJivup_l3plhBnMs8Zt68B29OUM86qxG6oGRICaFXG6jB2KAbW-tiyAijQ54TfoCOGRV5IijlvT-4j86835BYOSF8NDpC_RHn6Tjn9Bh9TT-gaiEYZ7Er8b22hW7wzOr31oQOG4uX665xpsATsCqubg28WeeNv46wLHWj49hj2eGF_tzxXxb_T2ZWmWJHwxNXb6HRBX41YY0BP-oACViouii481-0UlXGGgXVf5VnCNEHAr5pg9v67hQdllB5fbbvA_RyN11OHpL50_1scjNPgNM0JJAyxUapEpyJDGjMQ2ZU5kXGlSJUqjJTTI0BGMsyDrmQY0kF51IIXaRUUjZAlz-628a9t9qHVW280lUFVrvWr1gqBBNUZGmknu-prYyvWW0bU0PTrX7jZt86NYnn |
| CitedBy_id | crossref_primary_10_1080_14737159_2024_2305183 crossref_primary_10_1016_j_chest_2022_09_010 crossref_primary_10_1111_1759_7714_15160 crossref_primary_10_1089_ct_2021_33_444_446 crossref_primary_10_1210_clinem_dgac646 crossref_primary_10_3390_endocrines5030033 crossref_primary_10_3390_ijms222111829 crossref_primary_10_1007_s00330_022_09299_w crossref_primary_10_1177_10732748221135447 crossref_primary_10_1590_0102_311xpt131623 crossref_primary_10_3389_fpubh_2022_974359 crossref_primary_10_1371_journal_pone_0299685 crossref_primary_10_1016_j_xcrm_2025_102043 crossref_primary_10_3389_fonc_2025_1608963 crossref_primary_10_1155_2022_8030262 crossref_primary_10_1089_thy_2024_0239 crossref_primary_10_1016_S0140_6736_23_00020_X crossref_primary_10_3389_fonc_2022_852347 crossref_primary_10_1007_s10552_023_01694_y crossref_primary_10_1186_s12902_024_01670_w crossref_primary_10_1210_clinem_dgad722 crossref_primary_10_1016_j_coemr_2023_100472 crossref_primary_10_3389_fendo_2025_1514455 crossref_primary_10_3390_ijms26020759 crossref_primary_10_7189_jogh_14_04131 crossref_primary_10_1097_MED_0000000000000756 crossref_primary_10_1097_MED_0000000000000877 crossref_primary_10_3390_ijms26146987 crossref_primary_10_1089_thy_2024_0344 crossref_primary_10_1007_s12020_023_03578_2 crossref_primary_10_3389_fphar_2024_1323083 crossref_primary_10_1002_ijc_70088 crossref_primary_10_1177_09612033251345193 crossref_primary_10_1038_s41598_024_78179_8 crossref_primary_10_1016_j_otc_2025_03_020 crossref_primary_10_1089_thy_2021_0361 crossref_primary_10_1093_clinchem_hvad127 crossref_primary_10_1089_thy_2023_0497 crossref_primary_10_1186_s13256_023_04265_6 crossref_primary_10_1016_S2213_8587_24_00310_3 crossref_primary_10_3390_endocrines6020015 crossref_primary_10_1007_s12094_025_04034_5 crossref_primary_10_1186_s12902_025_01833_3 crossref_primary_10_1016_j_eprac_2022_01_013 crossref_primary_10_3390_ijms25137161 crossref_primary_10_1007_s40200_025_01581_0 crossref_primary_10_7759_cureus_92607 crossref_primary_10_1002_fsn3_3538 crossref_primary_10_3390_life13051077 crossref_primary_10_1089_ct_2022_34_246_249 crossref_primary_10_1186_s13044_024_00205_8 crossref_primary_10_1016_j_surge_2024_08_017 crossref_primary_10_1016_j_jval_2023_12_007 crossref_primary_10_1007_s11701_023_01810_9 crossref_primary_10_1177_01455613241228078 crossref_primary_10_1136_bmjebm_2023_112460 crossref_primary_10_1007_s13193_024_02021_w crossref_primary_10_7196_SAMJ_2023_v113i8_710 crossref_primary_10_1016_j_otot_2025_09_012 crossref_primary_10_3390_cells14120936 crossref_primary_10_1186_s12905_023_02205_6 crossref_primary_10_3322_caac_21708 crossref_primary_10_1002_wjs_12373 crossref_primary_10_3390_epidemiologia4020012 crossref_primary_10_61873_MQCB4262 crossref_primary_10_1089_thy_2024_0644 crossref_primary_10_3322_caac_21820 crossref_primary_10_3389_fpubh_2023_1267534 crossref_primary_10_3390_ijms26104646 crossref_primary_10_1007_s13304_022_01445_9 crossref_primary_10_1016_j_banm_2021_11_020 crossref_primary_10_1038_s41416_025_03028_y crossref_primary_10_3389_fonc_2024_1333094 crossref_primary_10_1002_ijc_34974 crossref_primary_10_1007_s42058_024_00163_y crossref_primary_10_1007_s00464_023_10603_y crossref_primary_10_3390_nu16223862 crossref_primary_10_1016_j_arthro_2021_10_004 crossref_primary_10_1016_S2213_8587_22_00048_1 crossref_primary_10_1001_jamanetworkopen_2024_54057 crossref_primary_10_1055_a_1676_9086 crossref_primary_10_3389_fgene_2022_1014323 crossref_primary_10_1016_j_semperi_2025_152042 crossref_primary_10_1111_cen_14896 crossref_primary_10_1186_s12893_025_02898_6 crossref_primary_10_1186_s12902_025_02038_4 crossref_primary_10_3389_fonc_2022_994728 crossref_primary_10_4103_ija_ija_1010_23 crossref_primary_10_1055_a_1887_4591 crossref_primary_10_1038_s41574_025_01168_y crossref_primary_10_3233_THC_240362 crossref_primary_10_1210_clinem_dgae454 crossref_primary_10_1186_s13044_025_00260_9 crossref_primary_10_3390_cancers16061101 crossref_primary_10_1016_j_acra_2024_12_009 crossref_primary_10_1186_s12885_024_13288_1 crossref_primary_10_3390_cancers17030378 crossref_primary_10_1016_j_eprac_2024_04_010 crossref_primary_10_3390_diagnostics14242775 crossref_primary_10_1186_s12964_024_01908_z crossref_primary_10_3322_caac_21763 crossref_primary_10_3892_ijmm_2023_5272 crossref_primary_10_3390_diagnostics15030287 crossref_primary_10_1371_journal_pone_0305944 crossref_primary_10_3390_antiox14091135 crossref_primary_10_1210_clinem_dgac468 crossref_primary_10_1002_wjs_12608 crossref_primary_10_3389_fendo_2022_987906 crossref_primary_10_1016_j_ijporl_2022_111325 crossref_primary_10_1016_j_prp_2024_155255 crossref_primary_10_1210_jendso_bvae060 crossref_primary_10_3389_fendo_2023_1261860 crossref_primary_10_1210_clinem_dgad314 crossref_primary_10_1371_journal_pone_0319872 crossref_primary_10_1002_cncr_35026 crossref_primary_10_3390_cancers17091543 crossref_primary_10_1245_s10434_025_17256_2 crossref_primary_10_12688_f1000research_128740_1 crossref_primary_10_1177_01455613241272476 crossref_primary_10_7759_cureus_34078 crossref_primary_10_1007_s12020_024_03802_7 crossref_primary_10_1016_j_heliyon_2024_e41284 crossref_primary_10_3322_caac_21871 crossref_primary_10_3390_ijerph192316203 crossref_primary_10_1016_j_ijporl_2024_112166 crossref_primary_10_1158_1078_0432_CCR_22_2976 crossref_primary_10_3389_fonc_2025_1549866 crossref_primary_10_3389_fendo_2021_738213 crossref_primary_10_1186_s12957_024_03541_z crossref_primary_10_3390_jcm13102904 crossref_primary_10_1111_coa_14075 crossref_primary_10_1210_clinem_dgad264 crossref_primary_10_3390_ijms24043148 crossref_primary_10_3389_fonc_2024_1383864 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1001/jamainternmed.2021.4804 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2168-6114 |
| ExternalDocumentID | 34459841 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA251566 |
| GroupedDBID | 0R~ 4.4 53G AAGZG AARDX AAWTL ABBLC ABJNI ABPMR ACDNT ACGFS ADBBV AENEX AFCHL AGFXO AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BRYMA C45 CGR CUY CVF EBD EBS ECM EIF EMOBN EX3 H13 HF~ NPM OB2 OBH OCB OGEVE OHH OVD PQQKQ RAJ SV3 TEORI WH7 WOW YCJ YYP 7X8 |
| ID | FETCH-LOGICAL-a415t-a52c235c64267a1114b71b8d74cc01bcf7c2c9aa22774a86b9b1644b66ed51b12 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 155 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000692207200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2168-6114 |
| IngestDate | Sun Aug 24 03:58:07 EDT 2025 Thu Jan 02 22:55:06 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a415t-a52c235c64267a1114b71b8d74cc01bcf7c2c9aa22774a86b9b1644b66ed51b12 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8406211 |
| PMID | 34459841 |
| PQID | 2566261675 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2566261675 pubmed_primary_34459841 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-10-01 |
| PublicationDateYYYYMMDD | 2021-10-01 |
| PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA internal medicine |
| PublicationTitleAlternate | JAMA Intern Med |
| PublicationYear | 2021 |
| SSID | ssj0000800433 |
| Score | 2.667271 |
| SecondaryResourceType | review_article |
| Snippet | Thyroid cancer is more common in women than in men, but the associated causes of these differences are not fully understood.
To compare sex-specific thyroid... Thyroid cancer is more common in women than in men, but the associated causes of these differences are not fully understood.ImportanceThyroid cancer is more... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1351 |
| SubjectTerms | Asymptomatic Diseases - epidemiology Autopsy - statistics & numerical data Cohort Studies Female Humans Incidence Male Middle Aged Neoplasm Grading Neoplasm Staging Patient Acceptance of Health Care - statistics & numerical data SEER Program - statistics & numerical data Sex Factors Thyroid Neoplasms - mortality Thyroid Neoplasms - pathology Tumor Burden |
| Title | Evaluation of Gender Inequity in Thyroid Cancer Diagnosis: Differences by Sex in US Thyroid Cancer Incidence Compared With a Meta-analysis of Subclinical Thyroid Cancer Rates at Autopsy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34459841 https://www.proquest.com/docview/2566261675 |
| Volume | 181 |
| WOSCitedRecordID | wos000692207200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1LT9wwEMetAhXqhUcp5VGqqdSroXac2MsFoQXUHnaFeIi9rWzHFrkkyyaL2I_Gt2OceEFCqlSplyiHvCRPxr8Zj-dPyE_pjcEoIKPSOE6FzCXVjBnKEU0To7hLpWnFJuRwqEaj3mVMuNWxrHLhE1tHnVc25MiPcGpG9mbItyeTBxpUo8LqapTQWCIrCaJMsGo5Uq85lkBDolWT5yxTGCUxsSjxio2HijbthvMORoqcHQrVCrb9BTXbKedi_X8_doOsRdiE0846NskHV34mq4O4nL5Fns9fe31D5aGTlYM_pXuYIZxDUcLN_XxaFTn0g3FM4awrzCvqYzz1catgDWYO1-4pXH97_f4WdECdbin0Y7k73BXNPWgYuEZTHZuihPejE1ts1Hz_lKuAxKAbOJ011aSefyG3F-c3_d80ajlQjYjQUJ1yy5PUYriTSbQGJoxkRuVSWPuLGeul5banNefIo1plpmcwkBMmy1yeMsP4Nlkuq9LtEEiRqJwPDU0FF14LkyjvZW6RfbgTWuySH4tBGeO_EhZAdOmqWT1-G5Zd8rUb2fGka-oxToRIe0qwvX-4e598CubS1fR9IysePYU7IB_tY1PU0--tEeJxeDl4AYnt6LE |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+Gender+Inequity+in+Thyroid+Cancer+Diagnosis%3A+Differences+by+Sex+in+US+Thyroid+Cancer+Incidence+Compared+With+a+Meta-analysis+of+Subclinical+Thyroid+Cancer+Rates+at+Autopsy&rft.jtitle=JAMA+internal+medicine&rft.au=LeClair%2C+Karissa&rft.au=Bell%2C+Katy+J+L&rft.au=Furuya-Kanamori%2C+Luis&rft.au=Doi%2C+Suhail+A&rft.date=2021-10-01&rft.issn=2168-6114&rft.eissn=2168-6114&rft.volume=181&rft.issue=10&rft.spage=1351&rft_id=info:doi/10.1001%2Fjamainternmed.2021.4804&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2168-6114&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2168-6114&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2168-6114&client=summon |